nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—CYP3A4—type 2 diabetes mellitus	0.122	1	CbGaD
Dabrafenib—SLCO1B3—Pioglitazone—type 2 diabetes mellitus	0.0594	0.101	CbGbCtD
Dabrafenib—SLCO1B3—Valsartan—type 2 diabetes mellitus	0.0484	0.082	CbGbCtD
Dabrafenib—SLCO1B1—Repaglinide—type 2 diabetes mellitus	0.0383	0.0648	CbGbCtD
Dabrafenib—SLCO1B1—Pioglitazone—type 2 diabetes mellitus	0.0346	0.0586	CbGbCtD
Dabrafenib—SLCO1B1—Rosiglitazone—type 2 diabetes mellitus	0.0319	0.054	CbGbCtD
Dabrafenib—SLCO1B1—Valsartan—type 2 diabetes mellitus	0.0282	0.0477	CbGbCtD
Dabrafenib—SLCO1B3—Losartan—type 2 diabetes mellitus	0.0278	0.0471	CbGbCtD
Dabrafenib—SLC22A6—Chlorpropamide—type 2 diabetes mellitus	0.0222	0.0377	CbGbCtD
Dabrafenib—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0203	0.0343	CbGbCtD
Dabrafenib—SLC22A6—Tolbutamide—type 2 diabetes mellitus	0.0198	0.0336	CbGbCtD
Dabrafenib—SLC22A6—Nateglinide—type 2 diabetes mellitus	0.0169	0.0285	CbGbCtD
Dabrafenib—SLCO1B1—Losartan—type 2 diabetes mellitus	0.0162	0.0274	CbGbCtD
Dabrafenib—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.0162	0.0274	CbGbCtD
Dabrafenib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0154	0.026	CbGbCtD
Dabrafenib—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.0146	0.0248	CbGbCtD
Dabrafenib—ABCG2—Glyburide—type 2 diabetes mellitus	0.0141	0.0238	CbGbCtD
Dabrafenib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0137	0.0232	CbGbCtD
Dabrafenib—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.0135	0.0229	CbGbCtD
Dabrafenib—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.013	0.0221	CbGbCtD
Dabrafenib—SLC22A6—Glyburide—type 2 diabetes mellitus	0.0114	0.0193	CbGbCtD
Dabrafenib—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.0106	0.018	CbGbCtD
Dabrafenib—SLC22A6—Losartan—type 2 diabetes mellitus	0.0104	0.0176	CbGbCtD
Dabrafenib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00991	0.0168	CbGbCtD
Dabrafenib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00921	0.0156	CbGbCtD
Dabrafenib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00821	0.0139	CbGbCtD
Dabrafenib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00751	0.0127	CbGbCtD
Dabrafenib—CYP2C8—Losartan—type 2 diabetes mellitus	0.00685	0.0116	CbGbCtD
Dabrafenib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00681	0.0115	CbGbCtD
Dabrafenib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00657	0.0111	CbGbCtD
Dabrafenib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00594	0.0101	CbGbCtD
Dabrafenib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00507	0.00859	CbGbCtD
Dabrafenib—ABCB1—Losartan—type 2 diabetes mellitus	0.00464	0.00785	CbGbCtD
Dabrafenib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0045	0.00762	CbGbCtD
Dabrafenib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00431	0.0073	CbGbCtD
Dabrafenib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00431	0.0073	CbGbCtD
Dabrafenib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00408	0.00691	CbGbCtD
Dabrafenib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00304	0.00515	CbGbCtD
Dabrafenib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00278	0.00471	CbGbCtD
Dabrafenib—LIMK1—adipose tissue—type 2 diabetes mellitus	0.00161	0.0695	CbGeAlD
Dabrafenib—SIK1—islet of Langerhans—type 2 diabetes mellitus	0.00131	0.0564	CbGeAlD
Dabrafenib—SIK1—nephron tubule—type 2 diabetes mellitus	0.00105	0.0454	CbGeAlD
Dabrafenib—RAF1—islet of Langerhans—type 2 diabetes mellitus	0.00104	0.0449	CbGeAlD
Dabrafenib—BRAF—adipose tissue—type 2 diabetes mellitus	0.000998	0.043	CbGeAlD
Dabrafenib—SIK1—kidney—type 2 diabetes mellitus	0.000926	0.0399	CbGeAlD
Dabrafenib—SIK1—pancreas—type 2 diabetes mellitus	0.00092	0.0396	CbGeAlD
Dabrafenib—SIK1—cortex of kidney—type 2 diabetes mellitus	0.000902	0.0389	CbGeAlD
Dabrafenib—RAF1—nephron tubule—type 2 diabetes mellitus	0.000839	0.0361	CbGeAlD
Dabrafenib—SIK1—adipose tissue—type 2 diabetes mellitus	0.000835	0.036	CbGeAlD
Dabrafenib—SLC22A6—nephron tubule—type 2 diabetes mellitus	0.000815	0.0351	CbGeAlD
Dabrafenib—RAF1—cardiovascular system—type 2 diabetes mellitus	0.000754	0.0325	CbGeAlD
Dabrafenib—RAF1—kidney—type 2 diabetes mellitus	0.000737	0.0318	CbGeAlD
Dabrafenib—RAF1—pancreas—type 2 diabetes mellitus	0.000733	0.0316	CbGeAlD
Dabrafenib—RAF1—cortex of kidney—type 2 diabetes mellitus	0.000718	0.0309	CbGeAlD
Dabrafenib—BRAF—liver—type 2 diabetes mellitus	0.0007	0.0301	CbGeAlD
Dabrafenib—SLC22A6—cortex of kidney—type 2 diabetes mellitus	0.000697	0.03	CbGeAlD
Dabrafenib—RAF1—adipose tissue—type 2 diabetes mellitus	0.000665	0.0286	CbGeAlD
Dabrafenib—SLCO1B3—liver—type 2 diabetes mellitus	0.000603	0.026	CbGeAlD
Dabrafenib—SIK1—liver—type 2 diabetes mellitus	0.000586	0.0252	CbGeAlD
Dabrafenib—SLCO1B1—kidney—type 2 diabetes mellitus	0.000552	0.0238	CbGeAlD
Dabrafenib—SLC22A8—nephron tubule—type 2 diabetes mellitus	0.000488	0.021	CbGeAlD
Dabrafenib—RAF1—liver—type 2 diabetes mellitus	0.000466	0.0201	CbGeAlD
Dabrafenib—SLC22A8—kidney—type 2 diabetes mellitus	0.000429	0.0185	CbGeAlD
Dabrafenib—SLC22A8—cortex of kidney—type 2 diabetes mellitus	0.000418	0.018	CbGeAlD
Dabrafenib—SLCO1B1—liver—type 2 diabetes mellitus	0.000349	0.015	CbGeAlD
Dabrafenib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000347	0.0149	CbGeAlD
Dabrafenib—CYP2C8—kidney—type 2 diabetes mellitus	0.000314	0.0135	CbGeAlD
Dabrafenib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000275	0.0118	CbGeAlD
Dabrafenib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000213	0.00916	CbGeAlD
Dabrafenib—CYP3A4—kidney—type 2 diabetes mellitus	0.000212	0.00915	CbGeAlD
Dabrafenib—CYP2C8—liver—type 2 diabetes mellitus	0.000198	0.00854	CbGeAlD
Dabrafenib—ABCG2—liver—type 2 diabetes mellitus	0.000193	0.0083	CbGeAlD
Dabrafenib—ABCB1—retina—type 2 diabetes mellitus	0.000182	0.00783	CbGeAlD
Dabrafenib—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000171	0.00737	CbGeAlD
Dabrafenib—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000154	0.00662	CbGeAlD
Dabrafenib—ABCB1—kidney—type 2 diabetes mellitus	0.00015	0.00648	CbGeAlD
Dabrafenib—ABCB1—pancreas—type 2 diabetes mellitus	0.000149	0.00644	CbGeAlD
Dabrafenib—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000146	0.00631	CbGeAlD
Dabrafenib—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000136	0.00584	CbGeAlD
Dabrafenib—CYP3A4—liver—type 2 diabetes mellitus	0.000134	0.00578	CbGeAlD
Dabrafenib—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000127	0.000848	CcSEcCtD
Dabrafenib—Myalgia—Orlistat—type 2 diabetes mellitus	0.000127	0.000847	CcSEcCtD
Dabrafenib—Epistaxis—Ramipril—type 2 diabetes mellitus	0.000127	0.000843	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000126	0.000841	CcSEcCtD
Dabrafenib—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000126	0.000838	CcSEcCtD
Dabrafenib—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000126	0.000836	CcSEcCtD
Dabrafenib—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000126	0.000836	CcSEcCtD
Dabrafenib—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.000125	0.000832	CcSEcCtD
Dabrafenib—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000124	0.000828	CcSEcCtD
Dabrafenib—Alopecia—Losartan—type 2 diabetes mellitus	0.000124	0.000827	CcSEcCtD
Dabrafenib—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000124	0.000826	CcSEcCtD
Dabrafenib—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000124	0.000824	CcSEcCtD
Dabrafenib—Vomiting—Glipizide—type 2 diabetes mellitus	0.000124	0.000823	CcSEcCtD
Dabrafenib—Oedema—Valsartan—type 2 diabetes mellitus	0.000123	0.000822	CcSEcCtD
Dabrafenib—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000123	0.00082	CcSEcCtD
Dabrafenib—Infection—Valsartan—type 2 diabetes mellitus	0.000123	0.000816	CcSEcCtD
Dabrafenib—Rash—Glipizide—type 2 diabetes mellitus	0.000123	0.000816	CcSEcCtD
Dabrafenib—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000123	0.000816	CcSEcCtD
Dabrafenib—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000122	0.000815	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000122	0.000815	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000122	0.000815	CcSEcCtD
Dabrafenib—Erythema—Losartan—type 2 diabetes mellitus	0.000122	0.000814	CcSEcCtD
Dabrafenib—Oedema—Orlistat—type 2 diabetes mellitus	0.000122	0.000812	CcSEcCtD
Dabrafenib—Headache—Glipizide—type 2 diabetes mellitus	0.000122	0.000811	CcSEcCtD
Dabrafenib—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000122	0.000809	CcSEcCtD
Dabrafenib—Infection—Orlistat—type 2 diabetes mellitus	0.000121	0.000807	CcSEcCtD
Dabrafenib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000121	0.000806	CcSEcCtD
Dabrafenib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.000121	0.000805	CcSEcCtD
Dabrafenib—Anaemia—Irbesartan—type 2 diabetes mellitus	0.00012	0.0008	CcSEcCtD
Dabrafenib—Dizziness—Glimepiride—type 2 diabetes mellitus	0.00012	0.000799	CcSEcCtD
Dabrafenib—Skin disorder—Valsartan—type 2 diabetes mellitus	0.00012	0.000798	CcSEcCtD
Dabrafenib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.00012	0.000796	CcSEcCtD
Dabrafenib—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00012	0.000796	CcSEcCtD
Dabrafenib—Hypertension—Metformin—type 2 diabetes mellitus	0.000119	0.000792	CcSEcCtD
Dabrafenib—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000119	0.00079	CcSEcCtD
Dabrafenib—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000118	0.000789	CcSEcCtD
Dabrafenib—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000118	0.000788	CcSEcCtD
Dabrafenib—Back pain—Losartan—type 2 diabetes mellitus	0.000118	0.000788	CcSEcCtD
Dabrafenib—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000118	0.000787	CcSEcCtD
Dabrafenib—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000118	0.000785	CcSEcCtD
Dabrafenib—Muscle spasms—Losartan—type 2 diabetes mellitus	0.000118	0.000783	CcSEcCtD
Dabrafenib—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000117	0.000782	CcSEcCtD
Dabrafenib—Myalgia—Metformin—type 2 diabetes mellitus	0.000117	0.000781	CcSEcCtD
Dabrafenib—Headache—Pioglitazone—type 2 diabetes mellitus	0.000117	0.000777	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000116	0.000775	CcSEcCtD
Dabrafenib—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000116	0.000775	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000116	0.000772	CcSEcCtD
Dabrafenib—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000116	0.000771	CcSEcCtD
Dabrafenib—Nausea—Glipizide—type 2 diabetes mellitus	0.000115	0.000769	CcSEcCtD
Dabrafenib—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000115	0.000768	CcSEcCtD
Dabrafenib—Hypotension—Valsartan—type 2 diabetes mellitus	0.000115	0.000768	CcSEcCtD
Dabrafenib—Vision blurred—Losartan—type 2 diabetes mellitus	0.000115	0.000768	CcSEcCtD
Dabrafenib—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000115	0.000766	CcSEcCtD
Dabrafenib—Constipation—Gliclazide—type 2 diabetes mellitus	0.000115	0.000765	CcSEcCtD
Dabrafenib—Rash—Glimepiride—type 2 diabetes mellitus	0.000114	0.000762	CcSEcCtD
Dabrafenib—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000114	0.000761	CcSEcCtD
Dabrafenib—Rash—Sitagliptin—type 2 diabetes mellitus	0.000114	0.000759	CcSEcCtD
Dabrafenib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000114	0.000758	CcSEcCtD
Dabrafenib—Headache—Glimepiride—type 2 diabetes mellitus	0.000114	0.000757	CcSEcCtD
Dabrafenib—Cough—Irbesartan—type 2 diabetes mellitus	0.000113	0.000755	CcSEcCtD
Dabrafenib—Headache—Sitagliptin—type 2 diabetes mellitus	0.000113	0.000754	CcSEcCtD
Dabrafenib—Anaemia—Losartan—type 2 diabetes mellitus	0.000113	0.000753	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000112	0.000749	CcSEcCtD
Dabrafenib—Oedema—Metformin—type 2 diabetes mellitus	0.000112	0.000748	CcSEcCtD
Dabrafenib—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000112	0.000747	CcSEcCtD
Dabrafenib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000112	0.000746	CcSEcCtD
Dabrafenib—Infection—Metformin—type 2 diabetes mellitus	0.000112	0.000743	CcSEcCtD
Dabrafenib—Insomnia—Valsartan—type 2 diabetes mellitus	0.000112	0.000743	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000111	0.00074	CcSEcCtD
Dabrafenib—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000111	0.000737	CcSEcCtD
Dabrafenib—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000111	0.000737	CcSEcCtD
Dabrafenib—Insomnia—Orlistat—type 2 diabetes mellitus	0.00011	0.000734	CcSEcCtD
Dabrafenib—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.00011	0.000734	CcSEcCtD
Dabrafenib—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.00011	0.000734	CcSEcCtD
Dabrafenib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.00011	0.000733	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.00011	0.000732	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.00011	0.000731	CcSEcCtD
Dabrafenib—Leukopenia—Losartan—type 2 diabetes mellitus	0.00011	0.000729	CcSEcCtD
Dabrafenib—Skin disorder—Metformin—type 2 diabetes mellitus	0.000109	0.000727	CcSEcCtD
Dabrafenib—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000109	0.000725	CcSEcCtD
Dabrafenib—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000109	0.000723	CcSEcCtD
Dabrafenib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000109	0.000723	CcSEcCtD
Dabrafenib—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000108	0.000721	CcSEcCtD
Dabrafenib—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000108	0.000721	CcSEcCtD
Dabrafenib—Nausea—Glimepiride—type 2 diabetes mellitus	0.000108	0.000717	CcSEcCtD
Dabrafenib—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000108	0.000717	CcSEcCtD
Dabrafenib—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000107	0.000715	CcSEcCtD
Dabrafenib—Asthenia—Glyburide—type 2 diabetes mellitus	0.000107	0.000715	CcSEcCtD
Dabrafenib—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000107	0.000714	CcSEcCtD
Dabrafenib—Cough—Losartan—type 2 diabetes mellitus	0.000107	0.000711	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000107	0.000709	CcSEcCtD
Dabrafenib—Alopecia—Ramipril—type 2 diabetes mellitus	0.000106	0.000709	CcSEcCtD
Dabrafenib—Fatigue—Valsartan—type 2 diabetes mellitus	0.000106	0.000709	CcSEcCtD
Dabrafenib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000106	0.000707	CcSEcCtD
Dabrafenib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000106	0.000707	CcSEcCtD
Dabrafenib—Oedema—Irbesartan—type 2 diabetes mellitus	0.000106	0.000706	CcSEcCtD
Dabrafenib—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000106	0.000706	CcSEcCtD
Dabrafenib—Pruritus—Glyburide—type 2 diabetes mellitus	0.000106	0.000705	CcSEcCtD
Dabrafenib—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000106	0.000703	CcSEcCtD
Dabrafenib—Constipation—Valsartan—type 2 diabetes mellitus	0.000106	0.000703	CcSEcCtD
Dabrafenib—Infection—Irbesartan—type 2 diabetes mellitus	0.000105	0.000702	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000105	0.000701	CcSEcCtD
Dabrafenib—Fatigue—Orlistat—type 2 diabetes mellitus	0.000105	0.0007	CcSEcCtD
Dabrafenib—Hypotension—Metformin—type 2 diabetes mellitus	0.000105	0.000699	CcSEcCtD
Dabrafenib—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000105	0.000698	CcSEcCtD
Dabrafenib—Erythema—Ramipril—type 2 diabetes mellitus	0.000105	0.000698	CcSEcCtD
Dabrafenib—Myalgia—Losartan—type 2 diabetes mellitus	0.000104	0.000693	CcSEcCtD
Dabrafenib—Arthralgia—Losartan—type 2 diabetes mellitus	0.000104	0.000693	CcSEcCtD
Dabrafenib—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000104	0.000693	CcSEcCtD
Dabrafenib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000104	0.000693	CcSEcCtD
Dabrafenib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000104	0.000691	CcSEcCtD
Dabrafenib—Rash—Bromocriptine—type 2 diabetes mellitus	0.000103	0.000687	CcSEcCtD
Dabrafenib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000103	0.000686	CcSEcCtD
Dabrafenib—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000103	0.000686	CcSEcCtD
Dabrafenib—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000103	0.000683	CcSEcCtD
Dabrafenib—Headache—Bromocriptine—type 2 diabetes mellitus	0.000103	0.000683	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000102	0.000682	CcSEcCtD
Dabrafenib—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000102	0.000682	CcSEcCtD
Dabrafenib—Dry mouth—Losartan—type 2 diabetes mellitus	0.000102	0.000678	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000101	0.000672	CcSEcCtD
Dabrafenib—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000101	0.000671	CcSEcCtD
Dabrafenib—Oedema—Losartan—type 2 diabetes mellitus	9.98e-05	0.000665	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	9.97e-05	0.000664	CcSEcCtD
Dabrafenib—Infection—Losartan—type 2 diabetes mellitus	9.92e-05	0.00066	CcSEcCtD
Dabrafenib—Hypotension—Irbesartan—type 2 diabetes mellitus	9.91e-05	0.00066	CcSEcCtD
Dabrafenib—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	9.9e-05	0.000659	CcSEcCtD
Dabrafenib—Nervous system disorder—Losartan—type 2 diabetes mellitus	9.79e-05	0.000652	CcSEcCtD
Dabrafenib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	9.78e-05	0.000651	CcSEcCtD
Dabrafenib—Decreased appetite—Metformin—type 2 diabetes mellitus	9.77e-05	0.000651	CcSEcCtD
Dabrafenib—Abdominal pain—Valsartan—type 2 diabetes mellitus	9.76e-05	0.00065	CcSEcCtD
Dabrafenib—Nausea—Bromocriptine—type 2 diabetes mellitus	9.72e-05	0.000647	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	9.71e-05	0.000646	CcSEcCtD
Dabrafenib—Fatigue—Metformin—type 2 diabetes mellitus	9.69e-05	0.000645	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	9.67e-05	0.000643	CcSEcCtD
Dabrafenib—Hyperhidrosis—Losartan—type 2 diabetes mellitus	9.65e-05	0.000643	CcSEcCtD
Dabrafenib—Abdominal pain—Orlistat—type 2 diabetes mellitus	9.64e-05	0.000642	CcSEcCtD
Dabrafenib—Body temperature increased—Orlistat—type 2 diabetes mellitus	9.64e-05	0.000642	CcSEcCtD
Dabrafenib—Asthenia—Gliclazide—type 2 diabetes mellitus	9.64e-05	0.000642	CcSEcCtD
Dabrafenib—Constipation—Metformin—type 2 diabetes mellitus	9.61e-05	0.00064	CcSEcCtD
Dabrafenib—Vomiting—Glyburide—type 2 diabetes mellitus	9.51e-05	0.000633	CcSEcCtD
Dabrafenib—ABCB1—liver—type 2 diabetes mellitus	9.51e-05	0.00409	CbGeAlD
Dabrafenib—Pruritus—Gliclazide—type 2 diabetes mellitus	9.51e-05	0.000633	CcSEcCtD
Dabrafenib—Rash—Glyburide—type 2 diabetes mellitus	9.43e-05	0.000628	CcSEcCtD
Dabrafenib—Dermatitis—Glyburide—type 2 diabetes mellitus	9.43e-05	0.000628	CcSEcCtD
Dabrafenib—Leukopenia—Ramipril—type 2 diabetes mellitus	9.39e-05	0.000625	CcSEcCtD
Dabrafenib—Headache—Glyburide—type 2 diabetes mellitus	9.37e-05	0.000624	CcSEcCtD
Dabrafenib—Hypotension—Losartan—type 2 diabetes mellitus	9.33e-05	0.000621	CcSEcCtD
Dabrafenib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	9.22e-05	0.000614	CcSEcCtD
Dabrafenib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	9.19e-05	0.000612	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	9.19e-05	0.000612	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	9.16e-05	0.00061	CcSEcCtD
Dabrafenib—Cough—Ramipril—type 2 diabetes mellitus	9.15e-05	0.000609	CcSEcCtD
Dabrafenib—Fatigue—Irbesartan—type 2 diabetes mellitus	9.15e-05	0.000609	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	9.1e-05	0.000606	CcSEcCtD
Dabrafenib—Hypersensitivity—Valsartan—type 2 diabetes mellitus	9.1e-05	0.000605	CcSEcCtD
Dabrafenib—Constipation—Irbesartan—type 2 diabetes mellitus	9.07e-05	0.000604	CcSEcCtD
Dabrafenib—Insomnia—Losartan—type 2 diabetes mellitus	9.03e-05	0.000601	CcSEcCtD
Dabrafenib—Hypersensitivity—Orlistat—type 2 diabetes mellitus	8.99e-05	0.000598	CcSEcCtD
Dabrafenib—Arthralgia—Ramipril—type 2 diabetes mellitus	8.93e-05	0.000595	CcSEcCtD
Dabrafenib—Myalgia—Ramipril—type 2 diabetes mellitus	8.93e-05	0.000595	CcSEcCtD
Dabrafenib—Nausea—Glyburide—type 2 diabetes mellitus	8.89e-05	0.000592	CcSEcCtD
Dabrafenib—Abdominal pain—Metformin—type 2 diabetes mellitus	8.89e-05	0.000592	CcSEcCtD
Dabrafenib—Dizziness—Gliclazide—type 2 diabetes mellitus	8.89e-05	0.000592	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	8.87e-05	0.00059	CcSEcCtD
Dabrafenib—Asthenia—Valsartan—type 2 diabetes mellitus	8.86e-05	0.00059	CcSEcCtD
Dabrafenib—Asthenia—Orlistat—type 2 diabetes mellitus	8.75e-05	0.000583	CcSEcCtD
Dabrafenib—Pruritus—Valsartan—type 2 diabetes mellitus	8.73e-05	0.000581	CcSEcCtD
Dabrafenib—Dry mouth—Ramipril—type 2 diabetes mellitus	8.73e-05	0.000581	CcSEcCtD
Dabrafenib—Decreased appetite—Losartan—type 2 diabetes mellitus	8.68e-05	0.000578	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	8.68e-05	0.000578	CcSEcCtD
Dabrafenib—Pruritus—Orlistat—type 2 diabetes mellitus	8.63e-05	0.000575	CcSEcCtD
Dabrafenib—Fatigue—Losartan—type 2 diabetes mellitus	8.61e-05	0.000573	CcSEcCtD
Dabrafenib—Oedema—Ramipril—type 2 diabetes mellitus	8.56e-05	0.00057	CcSEcCtD
Dabrafenib—Vomiting—Gliclazide—type 2 diabetes mellitus	8.54e-05	0.000569	CcSEcCtD
Dabrafenib—Constipation—Losartan—type 2 diabetes mellitus	8.54e-05	0.000568	CcSEcCtD
Dabrafenib—Rash—Gliclazide—type 2 diabetes mellitus	8.47e-05	0.000564	CcSEcCtD
Dabrafenib—Dermatitis—Gliclazide—type 2 diabetes mellitus	8.46e-05	0.000563	CcSEcCtD
Dabrafenib—Diarrhoea—Valsartan—type 2 diabetes mellitus	8.45e-05	0.000562	CcSEcCtD
Dabrafenib—Headache—Gliclazide—type 2 diabetes mellitus	8.42e-05	0.00056	CcSEcCtD
Dabrafenib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	8.4e-05	0.000559	CcSEcCtD
Dabrafenib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	8.39e-05	0.000558	CcSEcCtD
Dabrafenib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	8.39e-05	0.000558	CcSEcCtD
Dabrafenib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	8.38e-05	0.000558	CcSEcCtD
Dabrafenib—Diarrhoea—Orlistat—type 2 diabetes mellitus	8.35e-05	0.000556	CcSEcCtD
Dabrafenib—Skin disorder—Ramipril—type 2 diabetes mellitus	8.32e-05	0.000554	CcSEcCtD
Dabrafenib—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	8.28e-05	0.000551	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	8.16e-05	0.000543	CcSEcCtD
Dabrafenib—Dizziness—Valsartan—type 2 diabetes mellitus	8.16e-05	0.000543	CcSEcCtD
Dabrafenib—Dizziness—Orlistat—type 2 diabetes mellitus	8.07e-05	0.000537	CcSEcCtD
Dabrafenib—Asthenia—Metformin—type 2 diabetes mellitus	8.07e-05	0.000537	CcSEcCtD
Dabrafenib—Hypotension—Ramipril—type 2 diabetes mellitus	8e-05	0.000533	CcSEcCtD
Dabrafenib—Nausea—Gliclazide—type 2 diabetes mellitus	7.98e-05	0.000531	CcSEcCtD
Dabrafenib—Pruritus—Metformin—type 2 diabetes mellitus	7.95e-05	0.000529	CcSEcCtD
Dabrafenib—Body temperature increased—Losartan—type 2 diabetes mellitus	7.89e-05	0.000525	CcSEcCtD
Dabrafenib—Abdominal pain—Losartan—type 2 diabetes mellitus	7.89e-05	0.000525	CcSEcCtD
Dabrafenib—Vomiting—Valsartan—type 2 diabetes mellitus	7.85e-05	0.000523	CcSEcCtD
Dabrafenib—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	7.82e-05	0.00052	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	7.8e-05	0.000519	CcSEcCtD
Dabrafenib—Rash—Valsartan—type 2 diabetes mellitus	7.78e-05	0.000518	CcSEcCtD
Dabrafenib—Dermatitis—Valsartan—type 2 diabetes mellitus	7.78e-05	0.000518	CcSEcCtD
Dabrafenib—Vomiting—Orlistat—type 2 diabetes mellitus	7.76e-05	0.000516	CcSEcCtD
Dabrafenib—Insomnia—Ramipril—type 2 diabetes mellitus	7.74e-05	0.000515	CcSEcCtD
Dabrafenib—Headache—Valsartan—type 2 diabetes mellitus	7.73e-05	0.000515	CcSEcCtD
Dabrafenib—Diarrhoea—Metformin—type 2 diabetes mellitus	7.69e-05	0.000512	CcSEcCtD
Dabrafenib—Rash—Orlistat—type 2 diabetes mellitus	7.69e-05	0.000512	CcSEcCtD
Dabrafenib—Dermatitis—Orlistat—type 2 diabetes mellitus	7.68e-05	0.000512	CcSEcCtD
Dabrafenib—Headache—Orlistat—type 2 diabetes mellitus	7.64e-05	0.000509	CcSEcCtD
Dabrafenib—Asthenia—Irbesartan—type 2 diabetes mellitus	7.61e-05	0.000507	CcSEcCtD
Dabrafenib—Pruritus—Irbesartan—type 2 diabetes mellitus	7.51e-05	0.0005	CcSEcCtD
Dabrafenib—Decreased appetite—Ramipril—type 2 diabetes mellitus	7.44e-05	0.000495	CcSEcCtD
Dabrafenib—Dizziness—Metformin—type 2 diabetes mellitus	7.43e-05	0.000495	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	7.39e-05	0.000492	CcSEcCtD
Dabrafenib—Fatigue—Ramipril—type 2 diabetes mellitus	7.38e-05	0.000491	CcSEcCtD
Dabrafenib—Hypersensitivity—Losartan—type 2 diabetes mellitus	7.36e-05	0.00049	CcSEcCtD
Dabrafenib—Nausea—Valsartan—type 2 diabetes mellitus	7.33e-05	0.000488	CcSEcCtD
Dabrafenib—Constipation—Ramipril—type 2 diabetes mellitus	7.32e-05	0.000487	CcSEcCtD
Dabrafenib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	7.26e-05	0.000483	CcSEcCtD
Dabrafenib—Nausea—Orlistat—type 2 diabetes mellitus	7.25e-05	0.000482	CcSEcCtD
Dabrafenib—Asthenia—Losartan—type 2 diabetes mellitus	7.16e-05	0.000477	CcSEcCtD
Dabrafenib—Vomiting—Metformin—type 2 diabetes mellitus	7.15e-05	0.000476	CcSEcCtD
Dabrafenib—Rash—Metformin—type 2 diabetes mellitus	7.09e-05	0.000472	CcSEcCtD
Dabrafenib—Dermatitis—Metformin—type 2 diabetes mellitus	7.08e-05	0.000471	CcSEcCtD
Dabrafenib—Pruritus—Losartan—type 2 diabetes mellitus	7.06e-05	0.00047	CcSEcCtD
Dabrafenib—Headache—Metformin—type 2 diabetes mellitus	7.04e-05	0.000469	CcSEcCtD
Dabrafenib—Dizziness—Irbesartan—type 2 diabetes mellitus	7.02e-05	0.000467	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	7e-05	0.000466	CcSEcCtD
Dabrafenib—Diarrhoea—Losartan—type 2 diabetes mellitus	6.83e-05	0.000455	CcSEcCtD
Dabrafenib—Abdominal pain—Ramipril—type 2 diabetes mellitus	6.77e-05	0.000451	CcSEcCtD
Dabrafenib—Body temperature increased—Ramipril—type 2 diabetes mellitus	6.77e-05	0.000451	CcSEcCtD
Dabrafenib—Vomiting—Irbesartan—type 2 diabetes mellitus	6.75e-05	0.000449	CcSEcCtD
Dabrafenib—Rash—Irbesartan—type 2 diabetes mellitus	6.69e-05	0.000445	CcSEcCtD
Dabrafenib—Dermatitis—Irbesartan—type 2 diabetes mellitus	6.68e-05	0.000445	CcSEcCtD
Dabrafenib—Nausea—Metformin—type 2 diabetes mellitus	6.68e-05	0.000445	CcSEcCtD
Dabrafenib—Headache—Irbesartan—type 2 diabetes mellitus	6.65e-05	0.000442	CcSEcCtD
Dabrafenib—Dizziness—Losartan—type 2 diabetes mellitus	6.6e-05	0.00044	CcSEcCtD
Dabrafenib—Vomiting—Losartan—type 2 diabetes mellitus	6.35e-05	0.000423	CcSEcCtD
Dabrafenib—Hypersensitivity—Ramipril—type 2 diabetes mellitus	6.31e-05	0.00042	CcSEcCtD
Dabrafenib—Nausea—Irbesartan—type 2 diabetes mellitus	6.3e-05	0.00042	CcSEcCtD
Dabrafenib—Rash—Losartan—type 2 diabetes mellitus	6.3e-05	0.000419	CcSEcCtD
Dabrafenib—Dermatitis—Losartan—type 2 diabetes mellitus	6.29e-05	0.000419	CcSEcCtD
Dabrafenib—Headache—Losartan—type 2 diabetes mellitus	6.25e-05	0.000416	CcSEcCtD
Dabrafenib—Asthenia—Ramipril—type 2 diabetes mellitus	6.14e-05	0.000409	CcSEcCtD
Dabrafenib—Pruritus—Ramipril—type 2 diabetes mellitus	6.06e-05	0.000403	CcSEcCtD
Dabrafenib—Nausea—Losartan—type 2 diabetes mellitus	5.93e-05	0.000395	CcSEcCtD
Dabrafenib—Diarrhoea—Ramipril—type 2 diabetes mellitus	5.86e-05	0.00039	CcSEcCtD
Dabrafenib—Dizziness—Ramipril—type 2 diabetes mellitus	5.66e-05	0.000377	CcSEcCtD
Dabrafenib—Vomiting—Ramipril—type 2 diabetes mellitus	5.44e-05	0.000362	CcSEcCtD
Dabrafenib—Rash—Ramipril—type 2 diabetes mellitus	5.4e-05	0.000359	CcSEcCtD
Dabrafenib—Dermatitis—Ramipril—type 2 diabetes mellitus	5.39e-05	0.000359	CcSEcCtD
Dabrafenib—Headache—Ramipril—type 2 diabetes mellitus	5.36e-05	0.000357	CcSEcCtD
Dabrafenib—Nausea—Ramipril—type 2 diabetes mellitus	5.09e-05	0.000339	CcSEcCtD
Dabrafenib—RAF1—Immune System—PIK3R1—type 2 diabetes mellitus	4.5e-06	3.94e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	4.48e-06	3.92e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AGT—type 2 diabetes mellitus	4.46e-06	3.91e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—type 2 diabetes mellitus	4.46e-06	3.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SRC—type 2 diabetes mellitus	4.44e-06	3.89e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—type 2 diabetes mellitus	4.42e-06	3.87e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PSMD6—type 2 diabetes mellitus	4.4e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SNAP25—type 2 diabetes mellitus	4.4e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SREBF1—type 2 diabetes mellitus	4.4e-06	3.86e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.4e-06	3.85e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	4.39e-06	3.84e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	4.39e-06	3.84e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CALM1—type 2 diabetes mellitus	4.39e-06	3.84e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	4.38e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	4.38e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	4.38e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOE—type 2 diabetes mellitus	4.37e-06	3.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—type 2 diabetes mellitus	4.36e-06	3.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SERPINE1—type 2 diabetes mellitus	4.35e-06	3.81e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—type 2 diabetes mellitus	4.35e-06	3.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.34e-06	3.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—BCL2—type 2 diabetes mellitus	4.33e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CTGF—type 2 diabetes mellitus	4.32e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—APOA1—type 2 diabetes mellitus	4.32e-06	3.78e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	4.31e-06	3.77e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMGCR—type 2 diabetes mellitus	4.28e-06	3.75e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	4.28e-06	3.75e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	4.28e-06	3.75e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	4.28e-06	3.75e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARA—type 2 diabetes mellitus	4.27e-06	3.74e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.27e-06	3.74e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	4.25e-06	3.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—RELA—type 2 diabetes mellitus	4.23e-06	3.71e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	4.23e-06	3.7e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.2e-06	3.68e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.2e-06	3.68e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	4.2e-06	3.68e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	4.2e-06	3.68e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADRA2A—type 2 diabetes mellitus	4.19e-06	3.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	4.18e-06	3.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—C3—type 2 diabetes mellitus	4.17e-06	3.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3R1—type 2 diabetes mellitus	4.15e-06	3.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—type 2 diabetes mellitus	4.15e-06	3.64e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AGT—type 2 diabetes mellitus	4.13e-06	3.62e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	4.13e-06	3.61e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CALM1—type 2 diabetes mellitus	4.06e-06	3.56e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	4.05e-06	3.55e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOE—type 2 diabetes mellitus	4.05e-06	3.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	4.04e-06	3.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	4.04e-06	3.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2E1—type 2 diabetes mellitus	4.03e-06	3.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—type 2 diabetes mellitus	4.02e-06	3.52e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOA1—type 2 diabetes mellitus	4e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1A2—type 2 diabetes mellitus	3.98e-06	3.49e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC2A1—type 2 diabetes mellitus	3.98e-06	3.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.98e-06	3.48e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	3.97e-06	3.48e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—type 2 diabetes mellitus	3.97e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.97e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AGT—type 2 diabetes mellitus	3.96e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RELA—type 2 diabetes mellitus	3.96e-06	3.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—type 2 diabetes mellitus	3.94e-06	3.45e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	3.9e-06	3.42e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	3.9e-06	3.42e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	3.9e-06	3.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.89e-06	3.41e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—type 2 diabetes mellitus	3.89e-06	3.41e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP3A4—type 2 diabetes mellitus	3.88e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LEP—type 2 diabetes mellitus	3.88e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOE—type 2 diabetes mellitus	3.88e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	3.86e-06	3.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—type 2 diabetes mellitus	3.85e-06	3.37e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	3.84e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	3.84e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	3.84e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.84e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GCG—type 2 diabetes mellitus	3.82e-06	3.34e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC2A4—type 2 diabetes mellitus	3.82e-06	3.34e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PPARG—type 2 diabetes mellitus	3.81e-06	3.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—type 2 diabetes mellitus	3.8e-06	3.33e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	3.77e-06	3.3e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—INS—type 2 diabetes mellitus	3.73e-06	3.27e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	3.73e-06	3.27e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	3.67e-06	3.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	3.66e-06	3.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.66e-06	3.2e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	3.65e-06	3.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NFKB1—type 2 diabetes mellitus	3.57e-06	3.13e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.57e-06	3.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—type 2 diabetes mellitus	3.55e-06	3.11e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PPARG—type 2 diabetes mellitus	3.53e-06	3.09e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	3.51e-06	3.07e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	3.47e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	3.47e-06	3.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.46e-06	3.03e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—INS—type 2 diabetes mellitus	3.46e-06	3.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	3.44e-06	3.01e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—type 2 diabetes mellitus	3.42e-06	3e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.41e-06	2.98e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	3.38e-06	2.96e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.37e-06	2.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.34e-06	2.92e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	3.33e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	3.33e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—type 2 diabetes mellitus	3.33e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	3.32e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	3.32e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	3.32e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	3.32e-06	2.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—INS—type 2 diabetes mellitus	3.32e-06	2.9e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNB3—type 2 diabetes mellitus	3.29e-06	2.88e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.29e-06	2.88e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HMOX1—type 2 diabetes mellitus	3.28e-06	2.87e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3R1—type 2 diabetes mellitus	3.28e-06	2.87e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—type 2 diabetes mellitus	3.28e-06	2.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.26e-06	2.86e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAT—type 2 diabetes mellitus	3.23e-06	2.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.21e-06	2.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.2e-06	2.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.19e-06	2.79e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	3.18e-06	2.79e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—type 2 diabetes mellitus	3.17e-06	2.78e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOB—type 2 diabetes mellitus	3.14e-06	2.75e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—type 2 diabetes mellitus	3.11e-06	2.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—type 2 diabetes mellitus	3.07e-06	2.69e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—type 2 diabetes mellitus	3.05e-06	2.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.05e-06	2.67e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3R1—type 2 diabetes mellitus	3.03e-06	2.66e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	3.03e-06	2.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.03e-06	2.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—LPL—type 2 diabetes mellitus	3e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—type 2 diabetes mellitus	3e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—type 2 diabetes mellitus	2.99e-06	2.62e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	2.96e-06	2.59e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ADCY5—type 2 diabetes mellitus	2.93e-06	2.57e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GPX1—type 2 diabetes mellitus	2.92e-06	2.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—type 2 diabetes mellitus	2.92e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.91e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.91e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	2.87e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.87e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	2.85e-06	2.5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CD36—type 2 diabetes mellitus	2.85e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	2.82e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPP2CA—type 2 diabetes mellitus	2.81e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.78e-06	2.43e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	2.77e-06	2.43e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.76e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—type 2 diabetes mellitus	2.76e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—type 2 diabetes mellitus	2.75e-06	2.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.74e-06	2.4e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	2.73e-06	2.39e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.72e-06	2.39e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.7e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.7e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—type 2 diabetes mellitus	2.7e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—type 2 diabetes mellitus	2.69e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	2.66e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.65e-06	2.32e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARA—type 2 diabetes mellitus	2.65e-06	2.32e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.64e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.64e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.64e-06	2.31e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.62e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	2.61e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.57e-06	2.25e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	2.56e-06	2.25e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	2.56e-06	2.24e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	2.55e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.54e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	2.52e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	2.51e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	2.48e-06	2.17e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	2.48e-06	2.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.47e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.45e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.45e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.36e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.36e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.36e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	2.35e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.33e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.32e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.31e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	2.31e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.3e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.26e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	2.25e-06	1.97e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—type 2 diabetes mellitus	2.24e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—type 2 diabetes mellitus	2.24e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	2.23e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	2.2e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	2.19e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	2.19e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	2.16e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	2.16e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.15e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	2.15e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	2.14e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	2.14e-06	1.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.09e-06	1.83e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—type 2 diabetes mellitus	2.09e-06	1.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—type 2 diabetes mellitus	2.07e-06	1.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—type 2 diabetes mellitus	2.07e-06	1.81e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	2.05e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	2.05e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	1.97e-06	1.72e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.93e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.92e-06	1.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—type 2 diabetes mellitus	1.91e-06	1.67e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.91e-06	1.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.88e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	1.88e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	1.88e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.87e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.77e-06	1.55e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.77e-06	1.55e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.76e-06	1.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.74e-06	1.52e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	1.72e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.71e-06	1.5e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.68e-06	1.48e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.64e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.64e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.64e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.61e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.57e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.57e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.53e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.51e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—type 2 diabetes mellitus	1.51e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.5e-06	1.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.45e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.45e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.42e-06	1.24e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	1.39e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.38e-06	1.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.35e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.35e-06	1.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.34e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.33e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.17e-06	1.03e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.15e-06	1.01e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.06e-06	9.25e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.01e-06	8.85e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.01e-06	8.85e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	9.24e-07	8.09e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	8.65e-07	7.58e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	7.54e-07	6.6e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	4.64e-07	4.07e-06	CbGpPWpGaD
